Results 91 to 100 of about 590 (119)

Tralokinumab-related facial redness: a therapeutic challenge

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus, eczematous lesions, and lichenification. Treating patients with severe forms of AD is generally challenging for dermatologists.
Prieto-Torres, Lucía, Bularca, Elena, García-González, Sergio, Moratiel Pellitero, Alba, Villagrasa-Boli, Pablo   +4 more
core   +1 more source

Improvement of Dupilumab‐Induced Psoriasiform Eruption Following a Switch to Tralokinumab

JEADV Clinical Practice
Biologic therapies have transformed the management of atopic dermatitis (AD) and prurigo nodularis (PN), yet paradoxical adverse events such as dupilumab‐induced psoriasiform eruption (DPE) are increasingly recognized.
Masato Mizuashi, Yoshinori Sasaki
doaj   +1 more source

Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study

Dermatology and Therapy
Introduction Evaluating the real-world effectiveness, safety, and tolerability of targeted biologic and non-biologic therapies in patients with atopic dermatitis (AD) treated in routine clinical practice remains crucial.
Tiago Torres, Jensen Yeung, Vimal H. Prajapati, Simone Ribero, Anna Balato, Angelo Valerio Marzano, Maria João Cruz, Maria João Paiva Lopes, Elizabeth Lazaridou, Jose-Manuel Carrascosa, José Miguel Alvarenga, Pedro Farinha, Bruno Duarte, Monica Munera-Campos, Siddhartha Sood, Brian D. Rankin, Michela Ortoncelli, Stefano Caccavale, Silvia Mariel Ferrucci, Gilberto Pires Rosa, Athina Ioanna Daponte, Gianmarco Silvi, Ketty Peris, Niccolò Gori, Francesca Prignano, Antonio Kolios, Pedro Herranz, Stamatios Gregoriou, Natalia Rompoti, Spyridon Gkalpakiotis, Andrea Chiricozzi   +30 more
doaj   +1 more source

Dose-Exposure-Response Relationship of the Investigational Anti-Interleukin-13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma

, 2017
Interleukin (IL)-13 is involved in the pathogenesis of some types of asthma. Tralokinumab is a human immunoglobulin G(4) monoclonal antibody that specifically binds to IL-13.
Nicholas White, Paolo Vicini, Karlsson, Mats O,, Baverel, Paul G.,, White, Nicholas,, Agoram, Balaji,, Mats O. Karlsson, Balaji Agoram, Vicini, Paolo,, Paul G. Baverel   +9 more
core   +1 more source

Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis

Health Technology Assessment
Background Atopic dermatitis is a chronic relapsing inflammatory skin condition. One of the most common skin disorders in children, atopic dermatitis typically manifests before the age of 5 years, but it can develop at any age.
Steven J Edwards, Charlotta Karner, Tracey Jhita, Samantha Barton, Gemma Marceniuk, Zenas Z N Yiu, Miriam Wittmann   +6 more
doaj   +1 more source

Real-World Clinical Practice Evaluation of Tralokinumab in Atopic Dermatitis: A 52-Week Multi-Center Retrospective Study in the Basque Country

Background: Tralokinumab is an anti-IL-13 monoclonal antibody approved for moderate-to-severe atopic dermatitis (AD). While pivotal trials have demonstrated its efficacy, real-world data remain limited. Methods: We conducted a retrospective, multi-center
Nerea Ormaechea Pérez, Rosa María Izu Belloso, Nekane Martínez Peña, Manuel Pascual Ares, Vanesa Fatsini Blanch, Juan Antonio Ratón Nieto, Maider Pretel Irazabal, Marc Juliá Manresa   +7 more
core   +1 more source

Development of a psoriatic arthritis – like presentation under anti – IL-13 therapy with tralokinumab for atopic dermatitis

ObjectivesDual blockade of IL-4 and IL-13 in atopic dermatitis (AD) has been associated with activation of the IL-23/IL-17 axis, potentially leading to paradoxical psoriasis and psoriatic arthritis (PsA)-like presentation.
Di Matteo, Andrea, Kirkham, Bruce, Macleod, Tom, Lee, Sook Yan, Pink, Andrew, Marzo-Ortega, Helena, Blee, Ilona, Smith, Catherine; id_orcid, McGonagle, Dennis G., Woolf, Rick, De Marco, Gabriele, Palmer, Timothy, Meridor, Katya, Laws, Philip, Rowbotham, Emma, Abacar, Kerem, Freeston, Jane E., De Marco, G., McGonagle, D., Kirkham, B., Palmer, T., Di Matteo, A., Laws, P.M., Smith, C., Abacar, K., Meridor, K., Macleod, T., Marzo-Ortega, H., Rowbotham, E., Blee, I., Lee, S.Y., Pink, A., Freeston, J.E., Woolf, R.   +33 more
core   +1 more source

Tralokinumab for the Treatment of Adult Atopic Dermatitis in Special Populations

Journal of Asthma and Allergy
Luca Potestio,1,* Cataldo Patruno,2,* Stefano Dastoli,2 Claudio Brescia,1 Maddalena Napolitano1 1Section of Dermatology Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 2Department of Health Sciences ...
Potestio L, Patruno C, Dastoli S, Brescia C, Napolitano M   +4 more
doaj  

A deep dive into the clinical and biological effects of dupilumab and tralokinumab in atopic dermatitis: Insights from real-world studies to optimize treatment

Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disease, and its treatment landscape is rapidly evolving with new targeted therapies. This thesis aims to refine the use of the biological therapies dupilumab and tralokinumab in AD patients
de Bruin-Weller, Marjolein, Bakker, Daphne, van Wijk, Femke, Dekkers, Coco, Unit Opleiding Dermatologie, Infection & Immunity, de Graaf, M   +6 more
core  

Tralokinumab for moderate-to-severe atopic dermatitis: A viable option for dupilumab nonresponders

JAAD International
Christine T. Olagun-Samuel, BA, Christine C. Akoh, MD, PhD, Nnaemeka Anyanwu, BS, Elizabeth F. Sher, PhD, Carli D. Needle, BA, Jamie Widawsky, PA-C, MPAS, David E. Cohen, MD, MPH, Emily Milam, MD, Alexandra Flamm, MD, Vikash Oza, MD, Theodora K. Karagounis, MD, MS   +10 more
doaj   +1 more source